Pricing Log in Create free account
Friday 16 October 2026 Export ADCT’s income statement to Excel — free account

ADC Therapeutics SA

ADCT Healthcare Biotechnology

ADC Therapeutics SA’s revenue for fiscal 2025 (year ended December 2025) was $81.4 million, up 14.9% from fiscal 2024. In the quarter to June 2026, revenue grew 2.17%, EPS grew 78.0%, free cash flow grew 51.0% and total debt rose 1.87%, each against the same quarter a year earlier.

1.41 0.08 −5.37%
Market cap
$190.2M
P/E
0.0×
Fwd P/E
−1.2×
Dividend yield
—
F-score
5/9
Altman Z
−6.67
Beneish M
−2.09
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

ADC Therapeutics SA (ADCT) Business Profile

Updated before January 2025

Company Overview

ADC Therapeutics SA (ADCT) is a leading biotechnology company specializing in the development and commercialization of antibody-drug conjugates (ADCs) for the treatment of hematologic cancers and solid tumors. Founded in 2011, the company is headquartered in Lausanne, Switzerland, with additional offices and operations in the United States. ADCT was established by a team of seasoned professionals with extensive experience in oncology drug development, including its co-founders Dr. Chris Martin and Dr. Peter Buhl Jensen. The company is publicly traded on the New York Stock Exchange under the ticker symbol ADCT. Key leadership includes CEO Ameet Mallik, who brings a wealth of experience in the pharmaceutical and biotechnology sectors, and a dedicated team of executives and scientists committed to advancing cancer therapies.

Core Business Segments

ADCT focuses on the development of innovative antibody-drug conjugates, which are targeted therapies designed to deliver cytotoxic agents directly to cancer cells while minimizing damage to healthy tissues. The company’s core business segments include:

1. Hematologic Oncology

ADCT has developed a robust pipeline of ADCs targeting hematologic cancers, such as lymphomas and leukemias. Its flagship product, Zynlonta® (loncastuximab tesirine-lpyl), is an FDA-approved treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL). Zynlonta® represents a significant advancement in the treatment of aggressive B-cell malignancies.

2. Solid Tumor Oncology

ADCT is also advancing its pipeline of ADCs for the treatment of solid tumors. The company is conducting clinical trials for several investigational drugs targeting cancers such as breast, lung, and ovarian cancers. These therapies aim to address unmet medical needs in oncology.

3. Research and Development (R&D)

ADCT invests heavily in R&D to expand its pipeline of ADCs. The company collaborates with academic institutions, research organizations, and pharmaceutical companies to leverage cutting-edge technologies and discover new therapeutic targets.

Business Model

ADCT’s business model is centered on innovation, strategic partnerships, and commercialization. The company generates revenue through the sale of its approved products, licensing agreements, and milestone payments from collaborations. ADCT’s approach involves:

  • Targeted Therapy Development: Utilizing proprietary technology platforms to design ADCs that deliver potent cytotoxic agents directly to cancer cells.
  • Collaborations: Partnering with leading pharmaceutical companies and research institutions to accelerate drug development and expand its pipeline.
  • Commercialization: Building a strong commercial infrastructure to market its products globally, with a focus on the U.S. and European markets.

Strategic Direction

ADCT is committed to advancing its mission of transforming cancer treatment through innovative ADCs. The company’s strategic priorities include:

  • Pipeline Expansion: Developing next-generation ADCs with improved efficacy and safety profiles.
  • Global Market Penetration: Expanding the availability of its products in key markets, including Asia and Latin America.
  • Sustainability Goals: Implementing environmentally sustainable practices in its operations and supply chain.
  • New Therapeutic Areas: Exploring the potential of ADCs in non-oncology indications, such as autoimmune diseases.

Competitive Landscape

ADCT operates in a highly competitive biotechnology sector, facing competition from both established pharmaceutical companies and emerging biotech firms. Key competitors include:

  • Seagen Inc.: A leader in ADC technology with a strong portfolio of approved products.
  • ImmunoGen, Inc.: Focused on developing ADCs for cancer treatment.
  • Daiichi Sankyo: Known for its innovative ADCs targeting solid tumors.
  • Pfizer and Roche: Major pharmaceutical companies with significant investments in oncology and ADCs.

Despite the competition, ADCT differentiates itself through its proprietary technology platforms, focus on hematologic cancers, and commitment to addressing unmet medical needs.

Risk Factors

ADCT faces several risks that could impact its business operations and financial performance:

  • Regulatory Risks: Delays or failures in obtaining regulatory approvals for its investigational drugs.
  • Market Dependence: Heavy reliance on the success of Zynlonta® and other pipeline products.
  • Supply Chain Disruptions: Potential challenges in sourcing raw materials and manufacturing ADCs.
  • Competition: Intense competition from other biotechnology and pharmaceutical companies.
  • Financial Risks: High R&D costs and potential challenges in securing funding for future projects.

Recent Developments

ADCT has made significant progress in advancing its pipeline and expanding its commercial footprint. Recent developments include:

  • FDA Approval of Zynlonta®: The approval of Zynlonta® for DLBCL has positioned ADCT as a leader in hematologic oncology.
  • Clinical Trial Advancements: Positive interim results from clinical trials of investigational ADCs targeting solid tumors.
  • Strategic Partnerships: Collaborations with leading pharmaceutical companies to co-develop and commercialize ADCs.
  • Global Expansion: Efforts to launch Zynlonta® in European and Asian markets.

Investment Considerations

Strengths:

  • Innovative technology platform for ADC development.
  • Strong pipeline of investigational drugs targeting hematologic and solid tumors.
  • Experienced leadership team with a proven track record in oncology.
  • Growing revenue from the commercialization of Zynlonta®.

Risks:

  • Dependence on the success of a limited number of products.
  • High R&D costs and potential delays in clinical trials.
  • Competitive pressures from other ADC developers.
  • Regulatory and market access challenges in global markets.

Conclusion

ADC Therapeutics SA is at the forefront of innovation in oncology, leveraging its expertise in antibody-drug conjugates to develop targeted therapies for cancer patients. With a strong pipeline, strategic partnerships, and a commitment to addressing unmet medical needs, ADCT is well-positioned for future growth. However, the company must navigate regulatory, financial, and competitive challenges to achieve long-term success. Investors should weigh the company’s strengths and risks when considering ADCT as a potential investment opportunity.